246 related articles for article (PubMed ID: 26542347)
1. Oral delivery of zoledronic acid by non-covalent conjugation with lysine-deoxycholic acid: In vitro characterization and in vivo anti-osteoporotic efficacy in ovariectomized rats.
Jeon OC; Seo DH; Kim HS; Byun Y; Park JW
Eur J Pharm Sci; 2016 Jan; 82():1-10. PubMed ID: 26542347
[TBL] [Abstract][Full Text] [Related]
2. Preparation and in vivo evaluation of an orally available enteric-microencapsulated parathyroid hormone (1-34)-deoxycholic acid nanocomplex.
Hwang SR; Seo DH; Byun Y; Park JW
Int J Nanomedicine; 2016; 11():4231-46. PubMed ID: 27621618
[TBL] [Abstract][Full Text] [Related]
3. Development, in vitro and in vivo characterization of zoledronic acid functionalized hydroxyapatite nanoparticle based formulation for treatment of osteoporosis in animal model.
Khajuria DK; Razdan R; Mahapatra DR
Eur J Pharm Sci; 2015 Jan; 66():173-83. PubMed ID: 25444840
[TBL] [Abstract][Full Text] [Related]
4. Zoledronic acid suppresses callus remodeling but enhances callus strength in an osteoporotic rat model of fracture healing.
Hao Y; Wang X; Wang L; Lu Y; Mao Z; Ge S; Dai K
Bone; 2015 Dec; 81():702-711. PubMed ID: 26434668
[TBL] [Abstract][Full Text] [Related]
5. Sequential treatment with monofluorophosphate and zoledronic acid in osteoporotic rats.
Brance ML; Brun LR; Di Loreto VE; Lupo M; Rigalli A
Climacteric; 2014 Aug; 17(4):478-85. PubMed ID: 24205901
[TBL] [Abstract][Full Text] [Related]
6. Detecting early bone changes using in vivo micro-CT in ovariectomized, zoledronic acid-treated, and sham-operated rats.
Perilli E; Le V; Ma B; Salmon P; Reynolds K; Fazzalari NL
Osteoporos Int; 2010 Aug; 21(8):1371-82. PubMed ID: 19809776
[TBL] [Abstract][Full Text] [Related]
7. Influence of early and late zoledronic acid administration on vertebral structure and strength in ovariectomized rats.
Brouwers JE; van Rietbergen B; Bouxsein ML
Calcif Tissue Int; 2008 Sep; 83(3):186-91. PubMed ID: 18712432
[TBL] [Abstract][Full Text] [Related]
8. Bone degeneration and recovery after early and late bisphosphonate treatment of ovariectomized wistar rats assessed by in vivo micro-computed tomography.
Brouwers JE; Lambers FM; Gasser JA; van Rietbergen B; Huiskes R
Calcif Tissue Int; 2008 Mar; 82(3):202-11. PubMed ID: 18286219
[TBL] [Abstract][Full Text] [Related]
9. [Pharmacokinetics of Zoledronic acid[once-yearly bisphosphonate(intravenous infusion)].].
Tanaka S
Clin Calcium; 2016; 26(11):1605-1613. PubMed ID: 27777393
[TBL] [Abstract][Full Text] [Related]
10. Ionic complex of risedronate with positively charged deoxycholic acid derivative: evaluation of physicochemical properties and enhancement of intestinal absorption in rats.
Park JW; Byun Y
Arch Pharm Res; 2014 Dec; 37(12):1560-9. PubMed ID: 24254935
[TBL] [Abstract][Full Text] [Related]
11. Effect of systemic administered zoledronic acid on osseointegration of a titanium implant in ovariectomized rats.
Dikicier E; Karaçaylı Ü; Dikicier S; Günaydın Y
J Craniomaxillofac Surg; 2014 Oct; 42(7):1106-11. PubMed ID: 24530079
[TBL] [Abstract][Full Text] [Related]
12. The effect of bone morphometric changes on orthodontic tooth movement in an osteoporotic animal model.
Hashimoto M; Hotokezaka H; Sirisoontorn I; Nakano T; Arita K; Tanaka M; Yoshida N
Angle Orthod; 2013 Sep; 83(5):766-73. PubMed ID: 23445276
[TBL] [Abstract][Full Text] [Related]
13. Zoledronic acid in combination with alfacalcidol has additive effects on trabecular microarchitecture and mechanical properties in osteopenic ovariectomized rats.
Khajuria DK; Razdan R; Mahapatra DR
J Orthop Sci; 2014 Jul; 19(4):646-56. PubMed ID: 24668309
[TBL] [Abstract][Full Text] [Related]
14. Once-yearly administered intravenous zoledronic acid for postmenopausal osteoporosis.
Woodis CB
Ann Pharmacother; 2008 Jul; 42(7):1085-9. PubMed ID: 18505912
[TBL] [Abstract][Full Text] [Related]
15. [Evidences of safety and tolerability of the zoledronic acid 5 mg yearly in the post-menopausal osteoporosis: the HORIZON project].
Dalle Carbonare L; Bertoldo F; Lo Cascio V
Reumatismo; 2009; 61(1):54-64. PubMed ID: 19370189
[TBL] [Abstract][Full Text] [Related]
16. Does exercise modify the effects of zoledronic acid on bone mass, microarchitecture, biomechanics, and turnover in ovariectomized rats?
Lespessailles E; Jaffré C; Beaupied H; Nanyan P; Dolléans E; Benhamou CL; Courteix D
Calcif Tissue Int; 2009 Aug; 85(2):146-57. PubMed ID: 19609736
[TBL] [Abstract][Full Text] [Related]
17. Synthesis, characterization and evaluation of bone targeting salmon calcitonin analogs in normal and osteoporotic rats.
Bhandari KH; Newa M; Chapman J; Doschak MR
J Control Release; 2012 Feb; 158(1):44-52. PubMed ID: 22001608
[TBL] [Abstract][Full Text] [Related]
18. Zoledronic acid: a review of its use in the treatment of osteoporosis.
Deeks ED; Perry CM
Drugs Aging; 2008; 25(11):963-86. PubMed ID: 18947264
[TBL] [Abstract][Full Text] [Related]
19. Osteoprotective effect of propranolol in ovariectomized rats: a comparison with zoledronic acid and alfacalcidol.
Khajuria DK; Razdan R; Mahapatra DR; Bhat MR
J Orthop Sci; 2013 Sep; 18(5):832-42. PubMed ID: 23835529
[TBL] [Abstract][Full Text] [Related]
20. Loss of vertebral bone and mechanical strength in estrogen-deficient rats is prevented by long-term administration of zoledronic acid.
Glatt M; Pataki A; Evans GP; Hornby SB; Green JR
Osteoporos Int; 2004 Sep; 15(9):707-15. PubMed ID: 15024556
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
